secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-06-09T11:30:47+00:00
Accession:  0001213900-26-066526
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex initiates research coverage by Alliance Global Partners with BUY rating, $18 PT
--------------------------------------------------------------------------------

- Alliance Global Partners (AGP) initiates coverage with BUY rating and $18.00 price target as of June 8, 2026.
- Analyst James Molloy, AGP Managing Director and Senior Biotechnology Analyst, authored the report.
- Incannex's lead programs: IHL-42X for obstructive sleep apnoea (DReAMzz study) and PSX-001 synthetic psilocybin for generalized anxiety disorder.
- AGP has received compensation from Incannex for providing investment banking services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026066526/0001213900-26-066526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026066526/ea0293934-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-066526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer